Delivery Order SPE2D021D0005-SPE2D324F143K
Award Date
7/23/24
Potential Completion Date
7/26/24
Potential Value
$3.3K
Federal Agency
Medical Supply Chain
Awardee
Genentech Usa, Inc.
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
South San Francisco, CA 94080, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a delivery order awarded by the Defense Logistics Agency (DLA) to Genentech USA, Inc. for the pharmaceutical product Activase (alteplase). The $3,256.83 firm-fixed-price contract has an ultimate completion date of August 12, 2024. Genentech, a foreign-owned, for-profit manufacturer of pharmaceuticals and biologics, has provided a range of medical products to federal agencies including the Departments of Defense, Health and Human Services, Justice, and Veterans Affairs. Genentech holds...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Genentech USA, Inc., a foreign-owned, for-profit biotechnology and pharmaceutical manufacturer. The $872,420.96 firm fixed-price contract is for the provision of various medical supplies and pharmaceuticals, including critical medications such as Tamiflu, Activase, TNKase, and Xofluza, as well as routine medications like clonazepam and diazepam tablets. The contract has an ultimate completion date of June 22,...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of Activase 50 mg vials, a medication used to treat acute ischemic stroke. The contract has a ceiling value of $25,180.43 and a period of performance through May 12, 2025. It is a firm fixed-price contract, with no set-aside designation, indicating open competition. AmerisourceBergen...
This federal contract award is for the delivery of Activase (Alteplase) 100 mg vials to the Defense Logistics Agency (DLA), a defense agency within the U.S. Department of Defense. The prime contractor is Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Firm Fixed Price Delivery Order with a ceiling value of $5,737.53 and an ultimate completion date of January 4, 2022. It was awarded on January 3, 2022, and there was no set-aside...
This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of Activase (alteplase) 100 mg vials, a specialty medication used to treat acute ischemic stroke. The contract is a Delivery Order with a Firm Fixed Price pricing type, has no set-aside designation, and a ceiling value of $18,449.56. The period of performance runs from the award date of October...
This federal contract award is for the delivery of Activase 50 mg vials to the Defense Logistics Agency (DLA) Troop Support Medical. The contract, valued at $2,864.71, was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, and is a delivery order under a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA. The IDC, valued up to $999,999,999.00 through December 31, 2025, serves as the primary vehicle for Amerisourcebergen to provide a...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp for the supply of 50 mg vials of the pharmaceutical drug Activase (alteplase). The delivery order, valued at $7,191.80, is part of a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and the DLA Troop Support Medical, which has a ceiling value of up to $999,999,999 and runs through December 2025. This IDC enables the DLA to efficiently procure a comprehensive range of...
This federal contract award, valued at $11,871.88, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor. The contract is a delivery order for 4,568,055,020 units of Activase 50 mg vials, a medication used for the treatment of ischemic strokes. The contract is a firm fixed-price, non-set-aside award with a performance period ending on April 29, 2025. AmerisourceBergen Drug Corporation holds a substantial Indefinite Delivery...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp's Corporate Office Division, a major supplier of pharmaceutical products and medical supplies to the U.S. federal government. The contract is for the delivery of Activase 100 mg vials, a medication used for the treatment of ischemic stroke. The contract has a firm-fixed price of $11,427.70 and a completion date of June 11, 2024. Amerisourcebergen holds a significant Indefinite Delivery...
This is a delivery order (SPE2DB22D1106|SPE2DB24FFKP7) awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of 100 mg vials of Activase, a thrombolytic medication. The $15,239.26 fixed-price contract has a completion date of September 4, 2024. This delivery order is part of a larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at up to $999,999,999 through December 2025, which enables the...